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variantsLichen planus (LP) is an inﬂammatory skin condition with characteristic clinical and histopathological ﬁndings.
Classic LP typically presents as pruritic, polygonal, violaceous ﬂat-topped papules and plaques; many variants
in morphology and location also exist, including oral, nail, linear, annular, atrophic, hypertrophic, inverse, erup-
tive, bullous, ulcerative, lichen planus pigmentosus, lichen planopilaris, vulvovaginal, actinic, lichen planus-lupus
erythematosus overlap syndrome, and lichen planus pemphigoides. Clinical presentation of the rarer variant le-
sions may be largely dissimilar to classic LP and therefore difﬁcult to diagnose based solely on clinical examina-
tion. However, histopathological examination of LP and LP-variant lesions reveal similar features, aiding in the
proper diagnosis of the disease. Management of LP and LP variants aims to control symptoms and to decrease
time from onset to resolution; it often involves topical corticosteroids, but varies depending on the severity
and location of the lesion. The literature contains an array of reports on the variations in presentation and suc-
cessful management of LP and its variants. A familiarity with LP and its variants is important in achieving timely
recognition and management of the disease.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Lichen planus (LP) is an inﬂammatory skin conditionwith character-
istic clinical and histopathological ﬁndings that affects between 0.5 and
1% of the population. Classic LP typically presents as pruritic, polygonal,
violaceous ﬂat-topped papules and plaques; many variants in morphol-
ogy and location also exist, including oral, nail, linear, annular, atrophic,
hypertrophic, inverse, eruptive, bullous, ulcerative, LP pigmentosus, li-
chen planopilaris, vulvovaginal, actinic, lichen planus-lupus erythema-
tosus overlap syndrome, and lichen planus pemphigoides. Many of the
variants occur much more infrequently than classic LP. The rarity of
the variants and their atypical presentations make their timely diagno-
sis andmanagementmore difﬁcult in the clinical setting. Herein, we re-
view classic LP and its many variants reported in the literature
(Figs. 1–15).
Classic LP lesions commonly present with the four P’s: purple,
pruritis, polygonal, and papules/plaques. The papules often have dry,
shiny surfaces with branny scale that forms ﬁne, whitish streaks
known asWickham’s striae (Figs. 1–3). LP lesions are typically symmet-
ric in distribution and can affect any area of the body, but LP tends to
favor ﬂexural surfaces of the forearms, wrists, and ankles; the dorsal
surface of the hands; the shins; trunk; and sacral region. Involvement
of the oralmucosa is also common. Lesionsmay involve other cutaneousr Amgen and Lilly.
n behalf ofWomen'sDermatologic So(i.e., scalp, hair, and nails) and mucosal (i.e., genital, esophageal, and
conjunctival) sites, but, interestingly, the face is rarely affected.
LP affects patients of all ages, but up to 95% of all cases occur in adults,
with most patients presenting between the third and sixth decades of
life (Bilgili et al., 2012). While LP is generally considered an adult dis-
ease, 5 to 10% of cases do occur in children (Kumar et al., 1993; Luis-
Montoya et al., 2005), the majority of which are reported in India
(Handa and Sahoo, 2002; Kanwar and De, 2010; Kumar et al., 1993;
Pandhi et al., 2014; Sharma and Maheshwari, 1999). In the childhood
population, onset is more common in school-aged children, with mean
reported age ranging from 7 to 11.8 years old, though infantile cases
have rarely been reported (Balasubramaniam et al., 2008; Handa and
Sahoo, 2002; Kanwar and De, 2010; Luis-Montoya et al., 2005; Nanda
et al., 2001; Nnoruka, 2007; Pandhi et al., 2014; Walton et al., 2010).
While no speciﬁc gender predominance has been recognized, LP
may affect more adult females than adult males (Kyriakis et al., 2006).
Among childhood LP studies, no gender prevalence has been detected
(Balasubramaniam et al., 2008; Handa and Sahoo, 2002; Luis-Montoya
et al., 2005; Nanda et al., 2001; Pandhi et al., 2014; Walton et al.,
2010). In general, LP has not been shown to have a racial predilection;
however, certain populations seem to have a higher incidence of the
disease. In a U.S. study (Walton et al., 2010), a statistically signiﬁcant
greater number of LP patients were African American (72%) compared
to the general clinic population (21%). LP may also be more common
is patients of Indian descent, as ﬁve of the nine large childhood LP stud-
ies were conducted in India, where relatively large numbers of patients
were detected in short periods of time. Similarly, a study from the
United Kingdom found that children originating from the Indianciety. This is an openaccess article under the CCBY-NC-ND license (http://creativecommons.
Fig. 2. Lichenplanus. Photo courtesy ofDr. Justin Finch, University of ConnecticutDepartment
of Dermatology.
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city’s general child population (Balasubramaniam et al., 2008). There is
also a predominance of LP diagnosis reported in children of Arab and
Afro-Caribbean background.
The high proportion of cases reported among these populations sug-
gests a genetic susceptibility for LP. This idea is further supported by
cases of familial LP, reported in 1 to 4.3% of childhood LP series
(Kanwar and De, 2010; Nanda et al., 2001). However, familial cases
have not been reported in all series, and speciﬁc antigens have yet to
be determined. Pathogenicity of LP lesions involves the autoimmune-
mediated lysis of basal keratinocytes byCD8+ lymphocytes, thoughde-
ﬁnitive etiological triggers are still unknown. Case reports in both adults
and children have shown an association between LP and the following:
chronic liver diseases such as chronic active hepatitis (particularly
hepatitis C) and primary biliary cirrhosis; complication of hepatitis B
vaccination; viral and bacterial antigens; trauma (via the Koebner
phenomenon); metal ions; medications; and a variety of autoimmune
diseases such as autoimmune thyroiditis, myasthenia gravis, alopecia
areata, vitiligo, thymoma, and autoimmune polyendocrinopathy (Luis-
Montoya et al., 2005; Pandhi et al., 2014).
Histopathological features are consistent for LP and its variants. Light
microscopic evaluation of LP lesions shows circumscribed, wedge-
shaped hypergranulosis in the epidermis; marked hyperkeratosis;
and irregular sawtooth-like acanthosis of rete ridges. The dermal–
epidermal junction typically shows signs of vacuolar degeneration with
apoptotic keratinocytes, while the upper dermis characteristically con-
tains a dense, band-like lymphocytic inﬁltrate that can obscure the
dermal–epidermal junction. Civatte bodies, hypothesized to be apoptotic
keratinocytes ready for phagocytosis, can be seen in the epithelium and
upper dermis. Direct immunoﬂuorescence often reveals a large number
of IgM-staining cytoid bodies in the dermal papillae or peribasilar areas.
In general,management of classic cutaneous LP depends on the loca-
tion and severity of lesions and is largely based on clinical experience.
Most cutaneous LP lesions resolve spontaneously within a few years.
Goals of treatment include shortening the time from onset to resolution
and reducing symptoms, especially pruritus. Topical corticosteroids
(TCS), usually class I or II TCS, are the ﬁrst line of therapies and typically
sufﬁce to alleviate symptoms. In caseswhere TCS fail to control pruritus,
narrow-band UVB (NBUVB) often works well. Other second-lineFig. 1. Lichen planus. Photo courtesy of Dr. Justin Finch, University of Connecticut Depart-
ment of Dermatology.therapies include topical and systemic retinoids; systemic steroids;
and topical tacrolimus, metronidazole, griseofulvin, and cyclosporine.
Third-line therapies, includingpsoralenplusUVA(PUVA), thalidomide,my-
cophenolate mofetil, low molecular weight heparin, and iontophoresis,
have also been reported as effective (Rashid et al., 2008). Systemic treat-
ments are usually reserved for severe recalcitrant cases and are typically
used in combination with TCS or phototherapy. Post-inﬂammatory hyper-
pigmentation is often seen after treatment and may take years to fade.
The various cutaneous and mucosal variants of lichen planus will be
discussed below.
Oral lichen planus
Oral lichen planus (OLP) is a common presentation of lichen planus
that can occur alone, but often occurs concomitantly with skin lesions.
The oral form affects females more than males and commonly affects
patients of middle age (Wagner et al., 2013). Exact prevalence is un-
known, but has been estimated to be between 0.5% and 2.6% of various
populations. Speciﬁc etiology is controversial, but there is strong evi-
dence, as in classic LP, for immune-cell-mediated damage to basal
keratinocytes of the mucosa. Evidence suggests that various adhesion
molecules and cytokines including tumor necrosis factor alpha and
RANTES (regulated on activation normal T cell expressed and secreted)Fig. 3. Lichen planus. Photo courtesy of Dr. Justin Finch, University of Connecticut Depart-
ment of Dermatology.
Fig. 4. Reticular oral lichen planus. Photo courtesy of Dr. Justin Finch, University of
Connecticut Department of Dermatology. Fig. 6. Linear lichen planus. Photo courtesy of Dr. Marti Rothe, University of Connecticut
Department of Dermatology.
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and eosinophils. Premalignant potential, as well as the association
with hepatitis C virus of OLP, are still both very controversial (DeRossi
and Ciarrocca, 2005; Hiremath et al., 2011; Wagner et al., 2013).
OLP typically presents in several forms, which may appear alone or in
combination: reticular, erosive, atrophic, and plaque-like. Reticular OLP is
often asymptomatic and frequently is an incidentalﬁnding on examination.
Characteristic reticular lesions are bilateral and symmetricwith thin, slight-
ly raisedwhite lines orpapules that forma lace-likepattern,most common-
ly on the buccal mucosa (Fig. 4). Reticular OLP can be erythematous or
nonerythematous and may appear in an annular conﬁguration. Erosive
OLP lesions present as large areas of irregularly shaped ulcerations with
whitish pseudomembranes in combinationwith areas of severely erythem-
atous mucosa. Some lesions may appear with atrophy or radiating white
striae at the junction between involved and uninvolvedmucosa. Erosive le-
sions are typically painful and subject to irritation by dental hygiene prod-
ucts or foods. Other forms of OLP are less common. Differential diagnosis
for OLP lesions includes autoimmune vesicobullous disorders, chronic ul-
cerative stomatitis, chronic graft versus host disease, lupus erythematosus,
mucosal candidiasis, and oral hairy leukoplakia. AsOLP lesionsmay clinical-
ly resemble othermucosal diseases, includingmalignancies, histopatholog-
ical evaluation is warranted, particularly in isolatedmucosal disease. Direct
immunoﬂuorescence should be performed to rule out oral bullous pemphi-
goid or pemphigus vulgaris. Histological examination of OLP lesional tissue
reveals features similar to those of classic cutaneous LP.
Treatment of OLP in patients varies and depends on the severity of the
disease. Primary goals of therapy involve relieving symptoms and monito-
ring for changes suggestive of dysplasia. Typically, reticular lesions are notFig. 5. Anonychia in nail lichen planus. Photo courtesy of Dr. Justin Finch, University of
Connecticut Department of Dermatology.treated until they become inﬂamed, ulcerated, or sore (Le Cleach and
Chosidow, 2012; Wagner et al., 2013). While reticular lesions may resolve
spontaneously, other forms of OLP are much less likely to do so. First line
treatment includes TCS prescribed according to lesion severity (Ismail
et al., 2007). Topical immunomodulators can be applied directly or as a
rinse. Further, topical retinoids have been used as an alternative choice in
treating oral LP. Erosive lesions can be treatedwith TCS under occlusion. Re-
sistant lesions may require systemic steroid therapy or other systemic im-
munosuppressants for resolution (Farhi andDupin, 2010; Ismail et al., 2007).
Nail lichen planus
Nail involvement is a commonmanifestation of disseminated LP, af-
fecting up to 10% of patients with LP lesions involving other sites
(Nakamura et al., 2013). Nail LP may also be the only manifestation of
the condition. Nail LP typically appears during the ﬁfth or sixth decades
of life and affects genders equally (Tosti et al., 1993).
Typically, nail LP involves the ﬁngernails more than the toenails. Af-
fected nails presentwith longitudinal ridges, pitting, onychorrhexis, distal
splitting, and brown discoloration. Trachyonychia and onycholysis may
be apparent. Biopsy of involved tissue shows classic histopathological fea-
tures of LP. Dermoscopy may aid in evaluation of disease progress and
prognosis as changes in the nail matrix, nail bed, and perionychium can
be observedwith this technique (Nakamura et al., 2013). Earlymanifesta-
tions seen on dermoscopy include pitting of the nail matrix and
trachyonychia, while advanced disease often shows chromonychia,
lamina fragmentation, onycholysis, and splinter hemorrhage (Nakamura
et al., 2013). Differential diagnosis of nail lesions includes psoriasis,
onychomycosis, and nail-manifested alopecia areata.Fig. 7. Linear lichen planus. Photo courtesy of Dr. Justin Finch, University of Connecticut
Department of Dermatology.
Fig. 8. Annular lichen planus. Photo courtesy of Dr. Justin Finch, University of Connecticut
Department of Dermatology.
Fig. 10. Hypertrophic lichen planus. Photo courtesy of Dr. Justin Finch, University of
Connecticut Department of Dermatology.
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and prompt treatment is important. Conservative ﬁrst-line therapies
include superpotent TCS, often under occlusion, but these are usually
unsuccessful. Intralesional steroids are more effective; a single injection
of triamcinolone acetonide 10mg/ml into the proximal nail fold yielded
complete recovery within several months and lasted 2 years in one pa-
tient (Brauns et al., 2011). Alternatively, systemic steroid therapy with
oral prednisone or intramuscular injection of triamcinolone acetonide
has provided better outcomes. Unfortunately, recurrence has been
reported with all therapies for nail LP (Brauns et al., 2011).
Linear lichen planus
Linear LP is a rare variant that affects fewer than 1% of all patients
with LP. However, up to 10% of Japanese patients with LP may have
the linear form. Gender predominance has not been reported (Batra
et al., 2008). While many cases of linear LPmay be attributed to a linear
pattern of trauma via the Koebner phenomenon, other casesmay follow
a dermatomal or Blaschkoid pattern (Lehman et al., 2009). Dermatomal
or zosteriform patterns may affect skin previously involved in a zoster
infection (Pai and Pai, 2013). In linear LP lesions along Blaschko lines,Fig. 9. Atrophic lichen planus. Photo courtesy of Dr. Justin Finch, University of Connecticut
Department of Dermatology.a genetic component predisposing the involved tissue to a lichenoid
eruption is probable (Jury and Munro, 2000; Lakshmi et al., 2006).
Clinically, linear LP presents as classic LP papules along a line or band
pattern (Figs. 6-7). Lesions are usually unilateral, pruritic, and may
involve any area of the body (Hartl et al., 1999; Sciallis et al., 2005).
Patients may have isolated linear involvement or a combination of a
linear presentation with classic lesions elsewhere. Ipsilateral mucosal
involvement has also been reported. Differential diagnosis includes
inﬂammatory linear verrucous epidermal nevus, lichen striatus, linear
psoriasis, Blaschkitis, and linear Darier–White disease (Horowitz et al.,
2013). Histological examination of lesional tissue reveals features
identical to classic LP. Treatment is similar to that of classic LP lesions.
Annular lichen planus
Annular LP is a morphological variant of classic LP. Approximately 3 to
7% of patients with LP have the annular variant, although the true preva-
lence is likely underestimated (Badri et al., 2011). Reich et al. (2004)
observed a male predominance within their study cohort. Speciﬁc patho-
physiological cause for the annularmorphology of these lesions is notwell
understood, although several theories exist. The ring shape may develop
via the convergence of multiple lichenoid papules in a circular shape.
Alternatively, other lesions may form as a result of expansion of a papule
or plaque with central involution and an advancing raised border.
Annular LP lesions clinically present as red to purple circularmacules
or plaques with raised borders with or without central atrophy (Iga
et al., 2013; Morales-Callaghan et al., 2005) (Fig. 8). They can be single
or multiple and can each range between 2 and 8 cm in diameter (SerraoFig. 11. Generalized lichen planus. Photo courtesy of Dr. Marti Rothe, University of
Connecticut Department of Dermatology.
Fig. 12. Lichen planus pigmentosus inversus. Photo courtesy of Dr. Justin Finch, University
of Connecticut Department of Dermatology.
Fig. 14. Actinic lichen planus. Photo courtesy of Dr. Justin Finch, University of Connecticut
Department of Dermatology.
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annular has occurred in the literature, spurring the deﬁnition of a new
variant, atrophic annular lichen planus. Atrophic lesions are often asymp-
tomatic, although a portion of patients may experience pruritus. Genital
lesions, especially of the penis and scrotum, are common and may be
the underlying cause of a perceived male predominance (Badri et al.,
2011). Lesions also favor the intertriginous zones, including the axillae
and groin folds, but can also occur on the lips, trunk, or arms (Holmukhe
et al., 2012; Reich et al., 2004). Annular lesions are typically localized,
but generalized eruptions have been documented (Lee et al., 2011). Histo-
pathological examination reveals classic features of LP in the active edge of
the lesion. Tissue from the center of annular lesions shows a sparser
lymphocytic inﬁltrate and fewer Langerhans cells compared to tissue
from the advancing border regions (Yamanaka et al., 2004).
First line treatment of annular LP lesions in the adult patient is similar
to that of conventional LP, and involves topical corticosteroids (Badri
et al., 2011). Other successful approaches include systemic steroid
therapy combinedwith hydroxychloroquine and dapsone for generalized
annular LP and topical calcineurin inhibitors (Lee et al., 2011).
Atrophic lichen planus
Atrophic LP is a rare variant that may occur in areas previously af-
fected by other LP variants. There are very few reports of atrophic LPFig. 13. Lichen planopilaris. Photo courtesy of Dr. Marti Rothe, University of Connecticut
Department of Dermatology.in recent literature, making prevalence largely unknown. Etiology of
the atrophic subtype is not yet elucidated.
Cutaneous lesions of atrophic LP typically arise on skin affected by an
earlier LP lesion. They appear as well-demarcated white-bluish or brown
papules and plaques, andmost often occur after the resolution of annular
or ulcerative lesions (Wagner et al., 2013) (Fig. 9). Common sites include
the axillae and glans penis, lower extremities, or trunk (Tonsager and
Crutchﬁeld, 2004). Lakshmi et al. (2006) reported a case of atrophic LP
that also had a linear conﬁguration along the lines of Blaschko. This
patient presented with painful, atrophic macules, which progressed to
dark brown macules with marked atrophy. Diagnosis of this unusual
presentation was conﬁrmed when biopsy showed typical LP features.
First-line treatment is similar to that of other localized lichen
planus lesions.Hypertrophic lichen planus
The hypertrophic variant of LP, also called lichen planus verrucous or li-
chen planus hypertrophicus, is characterized by thickened papules and
plaques and is of unknown prevalence among adults. While exact patho-
physiologyhasnotbeenclariﬁed, eosinophilsmayplaya larger role inhyper-
trophic LP than in other variants (Alomari andMcNiff, 2014). It is likely that
the Koebner phenomenon also plays a role in the pathogenesis of these le-
sions. An association between hypertrophic LP lesions and malignant trans-
formation to squamous cell carcinoma (SCC) has been documented; about
10casesof squamouscell carcinomaoriginating fromhypertrophic LP lesions
have been documented in the literature since 2005. This associationmay be
explained by the chronic inﬂammation, a known risk factor for SCC, induced
by the intense, persistent scratching of these lesions (Krasowska et al., 2012).
Hypertrophic LP lesions typically present as red, yellow-gray, or red-
brown papules and plaques, most often on the pretibial area of the
lower extremity and the ankles. Lesions can also appear on other areas
of the lower limb, the upper limb, trunk, or in a generalized fashion.
They are ﬁrm to palpation and display a verrucous or hyperkeratoticFig. 15. Lichen planus/ lupus erythematosus overlap. Photo courtesy of Dr. Marti Rothe,
Univeristy of Connecticut Department of Dermatology.
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nature than classic LP lesions. Pretibial epidermolysis bullosa may
mimic the hypertrophic variant of LP if blistered lesions are not
apparent on clinical examination (Apalla et al., 2014). Additionally,
severe cases of hypertrophic LP may mimic well-differentiated SCC.
Pronounced epidermal hyperplasia and large rete ridges may be
present alongside classic histological LP ﬁndings in lesional tissue.
Pseudocarcinomatous hyperplasia may also be observed.
Treatment of hypertrophic LP lesions falls in linewith that of other LP
variants, with TCS used asﬁrst-line treatments. Successful treatment has
been achieved with mycophenolate mofetil, acitretin, and intralesional
steroid injections in combination with cryotherapy (Jaime et al., 2011;
Nousari et al., 1999; Wagner et al., 2013). Low-dose low-molecular-
weight heparin may be effective, but more evidence is needed before
use of this treatment becomes commonplace (Rai et al., 2002). Lesions
often leave behind hyperpigmentation and scarring after resolution.
Inverse lichen planus
Inverse LP is a variant affecting the intertriginous zones. Prevalence is
unknown, as is the exactmechanism behind these site-speciﬁc eruptions.
Inverse LP lesions are conﬁned to the intertiginous zones, including
the axillae, inguinal creases, gluteal cleft, limb ﬂexures, and submammary
region (Lehman et al., 2009). Lesions at these sitesmay lose their classic
morphology, presenting instead as erythematous lesions with poorly
deﬁned borders and licheniﬁcation (Wagner et al., 2013). Scale may
be absent due to the occlusive nature of these locations. Keratotic
papules or erosions may be present in individual lesions. Differential
diagnosis of inverse LP includes intertriginous manifestions of psoriasis
and inverse intertrigo.
Publications on treatment strategies for inverse LP are sparse. TCS
are an effective ﬁrst-line treatment as for other localized cutaneous LP
lesions. Additionally, Hoang et al. (2005) found improvement in a
patient with inverse LP with tacrolimus ointment.
Eruptive lichen planus
The eruptive variant of LP, also called exanthematous or generalized
LP, has rarely been reported in English-language literature in adults.
Etiology behind the generalized nature of this form of LP is not well un-
derstood. Fleming et al. (2011) reported a case of exanthematous LP
triggered by acupuncture, suggesting the inﬂuence of external factors
in precipitating an outbreak of this form of LP. Interesting, we recently
had a case of exanthematous LP at the University of Connecticut.
Clinically, the eruptive form of LP presents as rapidly spreading, dis-
seminated, erythematous, ﬂat-topped, polygonal papules or macules
that may become umbilicated and take on a violaceous color. Lesions
then resolve, leaving behind hyperpigmented macules (Liu et al.,
2013). Lesions may appear over the trunk, all four extremities, and
mucosal surfaces (Wagner et al., 2013). Multiple concomitant eruptive
lesions may display different morphology, suggesting a chronological
evolution of individual papules and macules (Fig. 11).
First-line treatment of eruptive LP in the adult population is not well
documented. Given the involved body surface area, the disseminated
nature of this variant likely requires systemic therapy if treatment is
desired. A tapered or pulsed systemic corticosteroid therapy alone or in
combination with PUVA therapy has been shown to be effective in re-
solving lesions and preventing new eruptions (Al-Mutairi et al., 2005;
Fleming et al., 2011). Similar effectswere foundwith pulsed itraconazole
therapy (Khandpur et al., 2009). Kanzaki et al. (1992) found topical ste-
roids, cyclosporine, and systemic griseofulvin to be ineffective, but found
success with etretinate. Other forms of UVA and UVB phototherapy may
also be helpful additions to systemic steroid therapy (Habib et al., 2005;
Wagner et al., 2013). As with most cases of LP, however, spontaneous
resolution may eventually occur, as was the case with our patient, who
experienced resolution after 8 weeks.Bullous lichen planus
The bullous form of LP is a rare variant characterized by develop-
ment of vesico-bullous lesions. Only a few cases have been reported in
the literature, making prevalence difﬁcult to estimate. However, the
etiology of bullae formation in bullous LP (BLP) is consistentwith exten-
sive vacuolar change of the basal cell layer (Gawkrodger et al., 1989). A
familial form of BLP has been reported in the literature and seems to
be associated with younger age of onset, increased severity, and
lengthened duration of the disease compared to that of individuals
without a similarly affected ﬁrst- or second-degree relative (Huang
et al., 2007). Familial formsmay be inherited in an autosomal dominant
pattern and display variable penetrance (Huang et al., 2005).
BLP typically presents as tense bullae on top of typical violaceous,
polygonal LP lesions. Many areas can be affected, including the dorsal
aspects of the hands and feet as well as the trunk, but the legs are
most common site. A bullous lesion superimposed on an asymptomatic
annular lichenoid lesion of the glans penis has also been reported
(Karthikeyan et al., 2003). BLP may be difﬁcult to distinguish from
lichen planus pemphigoides. However, BLP is a subepidermal bulla with
degeneration of the epidermal basal layer and classic LP features on histo-
logical examination; immunoﬂuorescence in BLP is negative, which is not
the case in lichen planus pemphigoides (Gawkrodger et al., 1989).
Treatment of BLP is similar to that of other variants.
Ulcerative lichen planus
The ulcerative or erosive variant of LPmay be found onmucosal sur-
faces, but also occurs on the plantar surface of the feet. Frequency is un-
known. Etiology behind the ulcerative nature of this variant is poorly
understood, but a potential inductive relationship between metoprolol
and erosive LP may exist (Salavastru and Tiplica, 2010).
Ulcerative LP presents clinically as ill-deﬁned, chronic, painful ulcers
of the plantar surface. Perilesional skin may be erythematous and scaly.
Walking may be impaired, toenails may be lost, and scarring may be
present (Salavastru and Tiplica, 2010). Histopathological examination
of lesional tissue reveals typical LP features.
Skin grafting to the eroded surface of ulcerative LP lesions has been a
therapeutic choice in the past (Wagner et al., 2013). However, less-
invasive methods of management have been on the rise. Ulcerative LP le-
sions are known to be challenging to treat due to resistance to common
local and systemic therapies. Topical tacrolimus ointment applied twice
daily may lead to near-complete re-epithelialization after 4 weeks in
some patients (Salavastru and Tiplica, 2010). Alternatively, medium dose
UVA-1 light therapy may produce improvement within several weeks
(Mansura et al., 2006). Therapieswithdocumentedpoor clinical responses
include systemic and topical steroids, occlusion under Unna boots,
antibiotics, oral retinoids, and topical PUVA therapy.
Lichen planus pigmentosus
Lichen planus pigmentosus (LPPi) is an uncommon variant that af-
fects all races but seems to favor darker-skinned individuals. It may be
more common in Indian and Middle Eastern populations and may
occur more frequently in females during the third and fourth decades
of life (Bourra and Leila, 2013). Frequency is unknown, as is the exact
cause of these lesions. It is possible that pigmentation of these lesions
is the result of extensive melanin incontinence. Viral infections (parti-
cularly hepatitis C); states of impaired carbohydrate metabolism;
drugs; topical application of mustard oil, alma oil, or henna dyes; and
sun exposure have all been proposed as triggering factors (Arnold and
Cooper, 2011; Torres et al., 2013). Multiple reports of this variant occur-
ring on supravenous skin have suggested that sites of venous dilation or
increased intravenous tension may increase skin temperature, which
may enhance an antigen immune response (Zhang and Zhu, 2011).
This would also explain a reported predominance of pigmented LP
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new variant known as lichen planus pigmentosus-inversus (Zhang and
Zhu, 2011) (Fig. 12).
Typical presentation of LPPi involves hyperpigmented dark brown
papules andmacules that are often asymptomatic. Lesions usually pres-
ent on sun-exposed sites including the face, neck, and upper extremi-
ties. Flexural area involvement has also been well documented.
Pigmentation patterns within lesions are often diffuse, while reticular,
blotchy, unilateral linear and perifollicular patterns are less common
(Vachiramon et al., 2010). Scalp, nail, or mucosal involvement is rare
(Seo et al., 2010). Differential diagnosis includes erythemadyschromicum
perstans, post-inﬂammatory hyperpigmentation, and ﬁgurate erythema
(Barros, 2013).
LPPimayhave a longer clinical course than other variants of LP. First-
line therapies are similar to other forms of LP. Successful management
has been achieved with TCS and tacrolimus ointment along with
acitretin (Rieder et al., 2013). Poor response to chloroquine has been re-
ported (Bourra and Leila, 2013). Phototherapy should be avoided due to
increased risk of pigmentation.
Lichen planopilaris
Lichen planopilaris (LPP) is a morphological variant of LP involving
the hair follicles that has been classiﬁed as a primary lymphocytic cica-
tricial alopecia. It occurs more frequently in Caucasian and Indian popu-
lations, with lower incidence in Asian populations. Affected female to
male ratio is 1.8:1. Most patients present between the second and
seventh decades of life (Lehman et al., 2009; Kang et al., 2008). Exact
etiology is poorly understood but is likely related to an inﬂammatory
response mediated by T lymphocytes targeting follicular antigens. It is
possible that infection, metal exposure, stress, and other factors may
act as sensitizers or triggers for the condition.
Clinically, patients with LPP present with whitish atrophic or
scarring patches on the scalp that may be accompanied by complaints
of increased hair shedding, itching, scaling, burning, and tenderness of
the scalp (Fig. 13). These subjective symptoms may worsen with expo-
sure to ultraviolet light, scalp irritation, sweating, and stress. Anagen
hairs may be pulled easily from active lesions. Lesions may be single
or multiple and commonly involve the vertex and parietal area. Three
groups of LPP exist: classic, frontal ﬁbrosing alopecia, and Graham-
Little-Piccardi-Lassueur syndrome. Classic LPP presents with scalp le-
sions and occasional extracranial LP lesions. Frontal ﬁbrosing alopecia
presents with progressive band-like scarring and hair loss from the
frontal hairline and mostly affects middle-aged women. Graham-
Little-Piccardi-Lassueur syndrome involves a triad of cicatricial alopecia
of the scalp as well as lichen planus of the skin with widespread follicu-
lar papules and a non-scarring hair loss of the axillary and pubic area
(Kang et al., 2008). Differential diagnosis of LPP includes other scarring
alopecias such as discoid lupus erythematosus and central centrifugal
cicatricial alopecia. Further, early LPP may be confused with seborrheic
dermatitis. Histopathological examination of early, active lesions re-
veals a lichenoid lymphocytic inﬁltrate affecting the infundibulum and
isthmus. The basement membrane zone, sebaceous glands, and root
sheaths are eventually lost and are replaced with ﬁbrosis and scarring
(Tandon et al., 2008). Histopathological examination of advanced le-
sions often reveals thick ﬁbrous tracts that have replaced destroyed
hair follicles (Cevasco et al., 2007).
First-line treatment formild tomoderate LPP involving less than 10%
of the scalp is often with superpotent TCS or intralesional corticosteroid
injections. Tetracycline derivatives or topical tacrolimus have shown
varied effectiveness (Blazek and Megahed, 2008; Cevasco et al., 2007;
Kang et al., 2008). Severe, rapidly progressing disease or patients with
severe symptomsmay require oral corticosteroids. Oral steroid therapy
can also be used as a bridge therapy until other agents have reached
maximal effectiveness (Kang et al., 2008). Another approach to treat-
ment in patients with extensive scalp involvement and lesions resistantto steroid therapy is with hydroxychloroquine, which may show im-
provement within several weeks but may take up to 6 to 12 months
until maximally effective (Kang et al, 2008; Samrao et al., 2010). Further
refractory cases of lichen planopilaris may be treated with immunosup-
pressive agents including cyclosporine and mycophenolate mofetil.
Third-line therapies such as systemic retinoids, griseofulvin, thalidomide,
dapsone, and minoxidil are still controversial (Kang et al., 2008). Some
success has been documented with the use of peroxisome proliferator-
activated receptor γ agonists like pioglitazone (Mirmirani and Karnik,
2009). Finally, a combination of dutasteride and pimecrolimus was re-
ported effective in a patient with the frontal ﬁbrosing variant of LPP
(Perez-Rodriguez et al., 2013).
Vulvovaginal lichen planus
Vulvovaginal LP is an uncommon variant that involves the vulva and
vagina. This disease seems to largely affect Caucasian women of peri-
menopausal age. Most patients present in the sixth decade of life
(Anderson et al., 2002). Incidence and etiology have not been
established. An association of vulvovaginal lesions and development of
vulval intraepithelial neoplasia may exist, but remains controversial
(Anderson et al., 2002; Neill and Lewis, 2008). Further, vulvovaginal
LP may occasionally be referred to vulvovaginal-gingival syndrome as
patients with vulvovaginal lesions often also have oral lesions, especial-
ly those affecting the gingival tissue.
A characteristic feature of the vulvovaginal variant of LP is a chronic
coursewith unexplained exacerbations, improvements, and remissions.
Women affected by vulvovaginal LP may present to a number of pro-
viders complaining of genital irritation, itching, burning, soreness, and
dyspareunia. These symptoms may be accompanied by abnormal,
often purulent discharge if the lesions involve the vagina. On physical
examination, ﬁndings may vary but usually suggest inﬂamed, erythem-
atous, and/or eroded epithelium. Eroded epitheliummay transform into
a reticulated white-gray lacy pattern. The disease may progress to vag-
inal adhesion, stenosis, or obliteration, making early diagnosis crucial
(Sobel, 2002). Differential diagnosis includes lichen sclerosis, autoim-
mune vesicobullous diseases, plasma cell vulvitis, Behcets disease, and
desquamative inﬂammatory vaginitis. Classic histological features of
LP may be obscured by the chronic and erosive nature of vulvovaginal
lesions, but hyperkeratosis and/or parakeratosis with varying degrees
of epidermal thinning and ulceration and lichenoid lymphocytic
inﬁltrate may be appreciated (Sobel, 2002).
Treatment of vulvovaginal LP is often challenging secondary to the
chronic nature of the disease and an apparent delay in diagnosis for
many women. There is a distinct need for randomized controlled trials
on various therapies in the management of vulvovaginal LP. Recently,
Bradford and Fischer (2013) demonstrated improvements in disease
course with initial aggressive therapy involving oral prednisolone,
with or without additional TCS application, and maintenance therapy
with weekly low-dose methotrexate when topical therapy was not
adequate. Alternatively, several studies have suggested that steroid
vaginal suppositories may be useful in controlling vulvovaginal LP le-
sions (Anderson et al., 2002; Sobel, 2002). Topical calcineurin inhibitors
may be useful in some patients, but may increase risk of neoplastic
transformation in genital tissue (Neill and Lewis, 2008). Other therapies
reported anecdotally in the literature include cyclosporine, dapsone,
griseofulvin, retinoid gel, thalidomide, antibiotics, hydroxychloroquine,
and other immunosuppressive agents (Sobel, 2002).
Actinic lichen planus
Actinic LP, also called lichen planus subtropicus or lichen planus
actinicus, is a rare variant that affects sun-exposed areas of the skin. Re-
ports of actinic LP are more common in darker-skinned African, Middle
Eastern, and Indian populations, while very few cases have been repor-
ted in Caucasians (Dekio et al., 2010). Eruptions occurmore oftenduring
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months. Actinic LP is more often reported in middle-aged patients and
may be more common in females than males (Prakash et al., 2013).
Exact pathogenesis is unknown but sun exposure is clearly a major pre-
cipitating factor. There are likely underlying genetic, infectious, environ-
mental, or hormonal factors that may predispose individuals to this
subtype of LP.
Clinically, actinic LP can present in three forms: annular, pigmented,
and dyschromic. The most common form, annular actinic LP, is charac-
terized by erythematous brownish plaques in an annular conﬁguration
with or without atrophy. Pigmented forms present as hypermelanotic
patches with a melasma-like appearance. Dyschromic-type actinic LP
lesions are the rarest and are characterized by whitish pinhead and co-
alescent papules (Mebazaa et al., 2010) (Fig. 14). Frequently affected
sites include the face, especially the forehead, cheeks and lips; the
upper chest; the extensor surface of the distal forearms; and the dorsal
surface of the hands. Actinic lesions are commonly asymptomatic and
may resemble actinic keratosis. Diagnosis is typically made based on
distribution in sun-exposed areas in combination with histological
ﬁndings consistent with those of classic LP.
Treatment for actinic LP lesions in the adult patient can vary. TCS, a
common therapeutic choice, have been shown to be effective in improv-
ing symptoms but are associatedwith relapseswith subsequent sun ex-
posure (Mebazaa et al., 2010). Improvement and prolonged remission
of lesions have been reported with topical pimecrolimus cream, cyclo-
sporine, or intralesional steroid injections in combination with sun-
screen (Ezzedine et al., 2009; Gallo et al., 2008). Varying results have
been foundwith oral retinoids, systemic steroid therapy, bismuth or ar-
senic compounds, hydroxychloroquine, and intense pulsed light
(Mebazaa et al., 2010; Santos-Juanes et al., 2010). Phototherapy should
be avoided in these patients as lesions are characteristically associated
with light exposure (Wagner et al., 2013). Sun avoidance is an essential
part of any therapeutic regimen targeted at improving actinic LP lesions.
Lichen planus-lupus erythematosus overlap syndrome
Lichen planus-lupus erythematosus overlap syndrome is a rare
variant that displays features of both LP and lupus erythematosus in
the same patient or in the same lesion in a single patient. Fewer than
50 cases have been reported in the literature before 2011 (Sekar et al.,
2011). There is much controversy over whether these two diseases ac-
tually overlap (necessitating the distinction of this overlap syndrome)
or if reports are simply coexistent episodes of these two diseases in
the same patient. Not surprisingly, no etiology has been clariﬁed. An au-
toimmune cause is likely due to the role of autoimmunity in both lupus
erythematosus and LP.
Lesionsmay present clinically with features of lupus erythematosus,
LP, or both. The distal arms, legs, face, and trunk may be involved.
Palmoplantar involvement may be characteristic of this syndrome
(Fig. 15). Cases have been reported in which patients have separate le-
sions consistentwith each disease; Demirci et al. (2011) reported aman
who had a malar butterﬂy rash and erythema of the back, consistent
with lupus erythematosus, and classic LP lesions on the extremities. Al-
ternatively, Nagao and Chen (2006) reported a case of genuine overlap
within a single lesion in a female patient. Histological examination,
again,may reveal characteristics of each disease or both simultaneously,
which may complicate diagnosis. Direct immunoﬂuorescence may be
essential in diagnosing this overlap syndrome (Camisa et al., 1984).
While some lesions still may only show features of one disease, some
may show granular deposits of immunoglobulins, complement compo-
nents and ﬁbrin along the dermal epidermal junction, and clusters of
IgM-staining colloid bodies, which would be suggestive of both lupus
erythematosus and lichen planus in the same tissue specimen (Nagao
and Chen, 2006).
Treatment of this variant often requires systemic therapy. However,
remarkable clinical improvement has been reported with high-potencyTCS and acitretin (Demirci et al., 2011; Lospinoso et al., 2013). Topical
tacrolimus ointment produced a moderate effect without eradicating
the lesions in the patient with genuine overlap discussed previously
(Nagao and Chen, 2006). Cyclosporine has also been reported to be
effective (Demirci et al., 2011).
Lichen planus pemphigoides
Lichen planus pemphigoides (LPPe) is a rare autoimmune subepi-
dermal blistering dermatosis that may be a unique variant of LP or a
heterogeneous blistering response to various antigens exposed by mul-
tiple injuries to the basal membrane zone. It is characterized by clinical,
histological, and immunopathological features of both classic LP and
bullous pemphigoid (Lehman et al., 2009). Exact prevalence is not
clear, but amale predominance has been suggested. Patients commonly
present in the fourth or ﬁfth decade of life and all races can be affected.
Etiology has not been fully elucidated; however, LPPe is likely the result
of an autoimmune response to hemidesmosomal- or keratinocyte-
derived antigens that have been exposed as a result of basal
keratinocyte apoptosis or injury (Hirayama et al., 2012; Kasperkiewicz
et al., 2012). LPPe eruption may be sporadic, a consequence of adverse
drug reaction (ACE inhibitors, cinnarizine, or simvastatin), or a compli-
cation of PUVA therapy. LPPe has also been linked to Castleman’s
disease and various neoplasms, including retroperitoneal round-cell
liposarcoma, chronic lymphocytic leukemia, and other soft-tissue
tumors (Anand et al., 2011).
LPPe lesions characteristically involve tense bullae affecting both un-
involved skin and skin affected by prior or current lichenoid eruptions.
Lesions commonly involve the extremities but may occur anywhere,
including the oral mucosa. Histological examination of lesional tissue
reveals characteristics of both lichen planus and bullous pemphigoid.
On direct immunoﬂuorescence, ﬁbrinogen deposition at the dermal–
epidermal junction and cytoid bodies are seen, consistent with lichen
planus, while probing for IgG and C3 is positive at the basement
membrane zone, which is consistent with bullous pemphigoid (Anand
et al., 2011).
One approach to the treatment of LPPe is to treat the existing LP and
avoid further immunostimulation. Alternatively, the lesions may be
treated as bullous pemphigoid lesions (Kasperkiewicz et al., 2012).
Treatment of LPPe with topical steroids may be effective, while some
cases require systemic steroid therapy. Cyclosporine seems to be a
beneﬁcial addition to systemic steroid therapy in recalcitrant cases.
Additionally, tetracycline, nicotinamide, isotretinoin, dapsone, and
other immunosuppressive drugs have produced varying results
(Anand et al., 2011). Due to the association of LPP eruptions with
Castleman’s disease, paraneoplastic pemphigus, and several malignan-
cies, patients with an LPPe diagnosis should undergo assessment for
unknown neoplasms (Hirayama et al., 2012).
Conclusion
Lichen planus is an inﬂammatory skin disease with characteristic
clinical and histopathological ﬁndings. In addition to classic LP, amyriad
of LP variants exist, including oral, nail, linear, annular, atrophic, hyper-
trophic, inverse, eruptive, bullous, ulcerative, LP pigmentosus, lichen
planopilaris, vulvovaginal, actinic, LP-lupus erythematosus overlap syn-
drome, and LP pemphigoides. The pruritic, polygonal, violaceous, ﬂat-
topped papules and plaques of classic LP are the most common presen-
tation of the disease, but morphology and location vary greatly among
the variants. However, histopathological ﬁndings among the variants
are largely consistent. Therefore, while clinical examinationmay be suf-
ﬁcient for diagnosis in some cases, histological examination is often
valuable in conﬁrming diagnosis of LP variants. Management of classic
LP and its variants is mostly consistent, with topical TCS as a ﬁrst-line
therapy among a diverse array of treatment options that have been re-
ported in the literature with varying degrees of success. Ultimately,
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